性与性别少数群体乳腺癌患者的诊断、治疗与结局
该暴露匹配回顾性病例对照研究纳入92例性与性别少数(SGM)乳腺癌患者与92例顺性别异性恋患者,按诊断年份、年龄、分期、ER及ERBB2状态匹配。SGM组从症状出现到诊断时间更长、更常拒绝肿瘤科医生推荐的治疗,复发风险更高。
要点
- SGM组从症状出现到诊断中位时间34天 vs 顺性别异性恋组64天,校正HR 0.65(95%CI 0.42-0.99;P=0.04)。
- SGM组拒绝肿瘤科医生推荐治疗35例(38%)vs 顺性别异性恋组18例(20%),校正OR 2.27(95%CI 1.09-4.74;P=0.03)。
- SGM组乳腺癌复发风险更高,校正HR 3.07(95%CI 1.56-6.03;P=0.001)。
核心结论
- 研究发现SGM组乳腺癌患者诊断延迟,复发风险约为顺性别异性恋患者的3倍(校正HR 3.07;95%CI 1.56-6.03;P=0.001),提示该群体诊疗存在差异,需进一步研究以指导干预。
研究设计与样本
- 暴露匹配回顾性病例对照研究,纳入2008年1月1日至2022年1月1日在一家学术医疗中心治疗的92例SGM组患者,按诊断年份、年龄、肿瘤分期、雌激素受体状态和ERBB2(HER2)状态与顺性别异性恋乳腺癌患者匹配。
主要发现
- 共184例患者,全部患者诊断时中位年龄49岁(IQR 43-56岁);SGM组中74例为女同性恋(80%)、12例为双性恋(13%)、6例为跨性别(6%)。
- SGM组从症状出现到诊断中位时间34天 vs 顺性别异性恋组64天,多因素校正HR 0.65(95%CI 0.42-0.99;P=0.04)。
- SGM组拒绝肿瘤科医生推荐的治疗方式35例(38%)vs 顺性别异性恋组18例(20%),多因素校正OR 2.27(95%CI 1.09-4.74;P=0.03)。
- SGM组乳腺癌复发风险更高,多因素校正HR 3.07(95%CI 1.56-6.03;P=0.001)。
- 结果已针对多重假设检验进行校正。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sexual orientation and gender identity data are not collected by most hospitals or cancer registries; thus, little is known about the quality of breast cancer treatment for patients from sex and gender minority (SGM) groups. OBJECTIVE: To evaluate the quality of breast cancer treatment and recurrence outcomes for patients from SGM groups compared with cisgender heterosexual patients. DESIGN, SETTING, AND PARTICIPANTS: Exposure-matched retrospective case-control study of 92 patients from SGM groups treated at an academic medical center from January 1, 2008, to January 1, 2022, matched to cisgender heterosexual patients with breast cancer by year of diagnosis, age, tumor stage, estrogen receptor status, and ERBB2 (HER2) status. MAIN OUTCOMES AND MEASURES: Patient demographic and clinical characteristics, as well as treatment quality, as measured by missed guideline-based breast cancer screening, appropriate referral for genetic counseling and testing, mastectomy vs lumpectomy, receipt of chest reconstruction, adjuvant radiation therapy after lumpectomy, neoadjuvant chemotherapy for stage III disease, antiestrogen therapy for at least 5 years for estrogen receptor-positive disease, ERBB2-directed therapy for ERBB2-positive disease, patient refusal of an oncologist-recommended treatment, time from symptom onset to tissue diagnosis, time from diagnosis to first treatment, and time from breast cancer diagnosis to first recurrence. Results were adjusted for multiple hypothesis testing. Compared with cisgender heterosexual patients, those from SGM groups were hypothesized to have disparities in 1 or more of these quality metrics. RESULTS: Ninety-two patients from SGM groups were matched to 92 cisgender heterosexual patients (n = 184). The median age at diagnosis for all patients was 49 years (IQR, 43-56 years); 74 were lesbian (80%), 12 were bisexual (13%), and 6 were transgender (6%). Compared with cisgender heterosexual patients, those from SGM groups experienced a delay in time from symptom onset to diagnosis (median time to diagnosis, 34 vs 64 days; multivariable adjusted hazard ratio, 0.65; 95% CI, 0.42-0.99; P = .04), were more likely to decline an oncologist-recommended treatment modality (35 [38%] vs 18 [20%]; multivariable adjusted odds ratio, 2.27; 95% CI, 1.09-4.74; P = .03), and were more likely to experience a breast cancer recurrence (multivariable adjusted hazard ratio, 3.07; 95% CI, 1.56-6.03; P = .001). CONCLUSIONS AND RELEVANCE: This study found that among patients with breast cancer, those from SGM groups experienced delayed diagnosis, with faster recurrence at a 3-fold higher rate compared with cisgender heterosexual patients. These results suggest disparities in the care of patients from SGM groups and warrant further study to inform interventions.
引用
- Eckhert E, Lansinger O, Ritter V, et al. Breast Cancer Diagnosis, Treatment, and Outcomes of Patients From Sex and Gender Minority Groups. JAMA Oncol. 2023. PMID: 36729432. doi:10.1001/jamaoncol.2022.7146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。